Program Description
Hidradenitis suppurativa (HS) is a chronic, noncontagious, inflammatory disorder that affects hair follicles. Painful lesions primarily occur in intertriginous areas and areas that are abundant in sweat glands. The chronicity of the disease and the scarring, limb contractures, raised nodules, skin deformities, along with drainage, and odor have a profound impact on the patient’s quality of life and can be mentally and physically debilitating. Patients can experience severe social stigma, low self-esteem, and sexual dysfunction, all leading to depression, social isolation, and decreased work productivity. Currently, HS is not curable, so the goal of treating the disease is to prevent worsening and lessen the symptoms. As HS triggers an immune response and inflammation, there is evidence that targeting IL-23 or IL-17 may be an effective treatment option for HS. It is important that pharmacists are aware of these emerging therapies and nuances with their safe and effective use. This webinar will review approaches for pharmacists to use their positions within specialty care teams to assist in the management of disease comorbidities with pharmacologic and nonpharmacologic management options for patients with HS.
Target audience: Specialty pharmacist
Type of activity: Application
Release date: December 14, 2022
Expiration date: February 14, 2023
Time to complete activity: 1.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathophysiology, disease progression, the long-term implications of undertreatment, and impact on quality of life for patients with hidradenitis suppurativa (HS)
- Analyze safety and efficacy data of new and emerging treatments for HS
- Illustrate the role of the pharmacist in optimizing patient outcomes through patient counseling as well as management of adverse effects, adherence, and comorbidities
Sarah Lant, PharmD
Clinical Pharmacist Specialist
UChicago Medicine
Chicago, Illinois
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-22-544-L01-P. The activity is available for CE credit through February 14, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Sarah Lant, PharmD, has the following financial relationship with commercial interests to disclose:
Other Support: Lilly
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms